#United States #New York #Inc. #SEC violations #Replimune Group #RP1 Trial

Legal Alert: Class Action for Replimune Group, Inc. Investors

In a significant development for investors in Replimune Group, Inc. (NASDAQ: REPL), a class action lawsuit is currently pending, focusing on whether the company misled shareholders regarding its regulatory strategy and clinical trial designs. The allegations stem from events that occurred between October 20, 2025, and April 10, 2026, during which many investors reportedly incurred substantial losses.

Allegations Against Replimune Group, Inc.

The crux of the issue lies in the company's development of its RP1 treatment, which was studied in a clinical trial alongside Bristol Myers Squibb's nivolumab. According to the legal notice provided by Levi & Korsinsky, LLP, the trial in question was a single-arm design that lacked the necessary rigor to determine the actual efficacy of RP1, as it did not effectively separate its impact from that of nivolumab.

The lawsuit contends that various flaws in the clinical trial design and regulatory submissions were not communicated to stakeholders, particularly concerns raised by the FDA regarding the response criteria used during the trial. Shareholders were misled, as the company presented its regulatory submissions as comprehensive responses to prior FDA feedback when, in reality, crucial transparency was lacking.

Clinical Trial Design and Regulatory Strategy Issues

Plaintiffs have pointed to several key operational deficiencies in the RP1 program:

• - The trial design was criticized for its inability to distinguish the benefits of RP1 from those of nivolumab.
• - Allegations emerged that the company did not follow the preferred approach of conducting randomized controlled trials, which the FDA had previously suggested.
• - The response assessment employed in the trial reportedly strayed from established guidelines, creating discrepancies in data interpretation.
• - Instead of using adequately planned Phase 3 data, the company relied on results from an early, unplanned interim analysis of a vastly smaller patient cohort than anticipated.

The fallout from these allegations has been significant, with the stock price of Replimune Group witnessing a drastic decline. Following a high of $10.73 per share on December 8, 2025, shares plummeted by approximately 84% during the specified class period, closing at just $1.70 by April 13, 2026.

What This Means for Investors

For shareholders wondering how to navigate their next steps, it is crucial to understand their eligibility for participation in this class action. If you purchased shares within the specified timeframe and experienced financial losses, you may have the right to seek compensation. Interested investors have until October 5, 2026, to file motions for lead plaintiff status in the ongoing case.

Steps to Take

1. Document Your Holdings: Investors should gather brokerage records that show their purchase dates, quantities of shares, and the prices paid.
2. Consult Legal Counsel: Engaging with specialists like those at Levi & Korsinsky can provide insight into your eligibility and the potential for financial recovery.
3. Stay Informed: Regular updates and legal advisories related to the lawsuit are critical for stakeholders. Investors should watch for developments in the case, especially those that could influence the outcome or settlement processes.

Conclusion

The situation surrounding Replimune Group, Inc. serves as an essential reminder for investors to remain vigilant regarding corporate communications and regulatory compliances. This lawsuit not only highlights potential missteps within a prominent biotech firm but also emphasizes the necessity for transparency in clinical trial reporting and adequate investor communication. Should you be impacted, do not hesitate to take informed action to protect your financial interests.